CAMBRIDGE, Mass., May 5, 2015 /PRNewswire/ -- Blueprint
Medicines (NASDAQ: BPMC) today announced the closing of its initial
public offering of 9,367,708 shares of common stock at a public
offering price of $18.00 per share,
including shares of common stock issued upon the full exercise by
the underwriters of their option to purchase additional shares. The
gross proceeds from the initial public offering to Blueprint
Medicines were approximately $168.6 million, before underwriting
discounts and estimated offering expenses.
Goldman, Sachs & Co. and Cowen and Company acted as joint
book-running managers for the offering. JMP Securities acted as a
co-manager for the offering. Wedbush PacGrow also acted as a
co-manager for the offering.
A registration statement relating to these securities has been
filed and was declared effective by the Securities and Exchange
Commission on April 29, 2015. The
offering was made only by means of a written prospectus forming
part of the effective registration statement. This press release
shall not constitute an offer to sell or a solicitation of an offer
to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
A copy of the final prospectus relating to the offering has been
filed with the Securities and Exchange Commission and may be
obtained from Goldman, Sachs & Co. by mail at 200 West Street,
New York, New York 10282,
Attention: Prospectus Department, by telephone at (866) 471-2526,
or by email at prospectus-ny@ny.email.gs.com, and from Cowen and
Company, LLC, c/o Broadridge Financial Services, 1155 Long Island
Avenue, Edgewood, NY 11717,
Attention: Prospectus Department, by telephone at (631) 274-2806,
or by fax at (631) 254-7140.
About Blueprint Medicines
Blueprint Medicines makes
kinase drugs to treat patients with genomically defined diseases.
Led by a team of industry innovators, Blueprint Medicines
integrates a novel target discovery engine and a proprietary
compound library to understand the blueprint of cancer and craft
highly selective therapies. This empowers the Blueprint Medicines
team to develop patient-defined medicines aimed at eradicating
cancer.
Contact:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com
Media:
Beth Keshishian
inVentiv Health PR
212-229-8417
beth.keshishian@inventivhealth.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-closing-of-initial-public-offering-300077944.html
SOURCE Blueprint Medicines